[1]李佳颖,李春霖,王玉莹,等.鲍曼不动杆菌的单药治疗及其联合使用的研究[J].医学信息,2019,32(05):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
 LI Jia-ying,LI Chun-lin,WANG Yu-ying,et al.Monotherapy of Acinetobacter Baumannii and Its Combined Use[J].Medical Information,2019,32(05):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
点击复制

鲍曼不动杆菌的单药治疗及其联合使用的研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年05期
页码:
48
栏目:
综述
出版日期:
2019-03-01

文章信息/Info

Title:
Monotherapy of Acinetobacter Baumannii and Its Combined Use
文章编号:
1006-1959(2019)05-0048-05
作者:
李佳颖李春霖王玉莹李春江
(佳木斯大学,黑龙江 佳木斯 154000)
Author(s):
LI Jia-yingLI Chun-linWANG Yu-yingLI Chun-jiang
(Jiamusi University,Jiamusi 154000,Heilongjiang,China)
关键词:
鲍曼不动杆菌耐药性联合疗法
Keywords:
Acinetobacter baumanniiDrug resistanceCombination therapy
分类号:
R446.5
DOI:
10.3969/j.issn.1006-1959.2019.05.016
文献标志码:
A
摘要:
鲍曼不动杆菌的环境适应能力及耐药能力强,可引发一系列感染,给临床治疗带来了巨大的挑战。随着各种广谱抗生素,特别是碳青霉烯类的广泛应用,使其耐药性不断增强。鉴于新型药物的的缺乏,临床常用药物联合治疗,目前联合治疗似已显现了更高的杀菌活性,但具体的效果还有待进一步证实。针对鲍曼不动杆菌的用药治疗进行综述,从而为防治相关感染提供理论基础。
Abstract:
Acinetobacter baumannii has a strong environmental adaptability and drug resistance, which can cause a series of infections, which brings great challenges to clinical treatment. With the wide application of various broad-spectrum antibiotics, especially carbapenems, the drug resistance is increasing. In view of the lack of new drugs and the combination of commonly used drugs in the clinic, the current combination therapy seems to have a higher bactericidal activity, but the specific effects need to be further confirmed. A review of the treatment of Acinetobacter baumannii provides a theoretical basis for the prevention and treatment of related infections.

参考文献/References:


[1]王姊娟,邹清华.鲍曼不动杆菌的耐药机制及其治疗药物[J].微生物学免疫学进展,2015(6):70-75.
[2]胡付品 译.2005-2014年CHINET中国细菌耐药性监测网5种重要临床分离菌的耐药性变迁[J].中国感染与化疗杂志,2017,17(1):93-99.
[3]Ece G,Samlioglu P,Atalay S,et al.Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care centre in Western Turkey[J].Infez Med,2014,22(1):36.
[4]王丽娟.多重耐药鲍曼不动杆菌关键耐药基因的研究[D].蚌埠医学院,2013.
[5]Lynch JP,Zhanel GG,Clark NM.Infections Due to Acinetobacter baumannii in the ICU: Treatment Options[J].Seminars in Respiratory & Critical Care Medicine,2017,38(3):311-325.
[6]Tumbarello M,Pascale GD,Trecarichi EM,et al.Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria[J].Chest,2013,144(6):1768-1775.
[7]Arnold HM,Sawyer AM,Kollef MH.Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia[J].Respiratory Care,2012,57(8):1226-1233.
[8]Yao ZY,Jia Z,Xie YH,et al.Analgesic effect of dezocine in different doses on elderly patients undergoing abdominal operation under general anesthesia and its influence on stress response to postoperative tracheal extubation[J].European Review for Medical & Pharmacological Sciences,2017,21(22):5223.
[9]胡付品,郭燕,朱德妹,等.2017年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2018,18(3):241-251.
[10]张辉,张小江,徐英春.2012年中国CHINET不动杆菌属细菌耐药性监测[J].中国感染与化疗杂志,2014,13(5):392-397.
[11]Pulido MR,González-Galán V,Fernández CF,et al.Application of the BioFire FilmArray Blood Culture Identification Panel for Rapid Identification of the Causative Agents of Ventilator Associated Pneumonia[J].Clin Microbiol Infect,2018,24(11):1213.e1-1213.e4.
[12]Betrosian AP,Frantzeska F,Anna X,et al.High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii[J].Scandinavian Journal of Infectious Diseases,2007,39(1):38.
[13]Doi Y,Murray GL,Peleg AY.Acinetobacter baumannii: Evolution of Antimicrobial Resistance-Treatment Options[J].Seminars in Respiratory & Critical Care Medicine,2015,36(1):85-98.
[14]Goff DA,Bauer KA,Mangino JE.Bad Bugs Need Old Drugs: A Stewardship Program’s Evaluation of Minocycline for Multidrug-Resistant Acinetobacter baumannii Infections[J].Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America,2014,59 Suppl 6(suppl_6):S381.
[15]贺霞,周庄,张琰,等.头孢哌酮/舒巴坦钠联合米诺环素治疗老年泛耐药鲍曼不动杆菌肺炎的疗效观察[J].检验医学与临床,2015(13):1876-1877.
[16]Ni W,Han Y,Jin Z,et al.Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii,infections:a systematic review and meta-analysis[J].International Journal of Antimicrobial Agents,2016,47(2):107-116.
[17]Shin JA,Chang YS,Kim HJ,et al.Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J].Yonsei Medical Journal,2012,53(5):974-984.
[18]詹伟锋,何楷然,刘新强.头孢哌酮-舒巴坦结合替加环素治疗ICU泛耐药鲍曼不动杆菌感染的效果[J]. 广东医学,2014(10):1540-1541.
[19]Soudeiha MAH,Dahdouh EA,Azar E,et al.In vitroEvaluation of the Colistin-Carbapenem Combination in Clinical Isolates ofA. baumanniiUsing the Checkerboard, Etest, and Time-Kill Curve Techniques[J].Frontiers in Cellular & Infection Microbiology,2017(7):209.
[20]Wei W,Yang H,Hu L,et al.Activity of levofloxacin in combination with colistin against Acinetobacter baumannii:In vitro and in a Galleria mellonella model[J].J Microbiolo Immunol Infect,2017,50(6):821-830.
[21]Safarika A,Galani I,Pistiki A,et al.Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii:synergism with imipenem and colistin[J].Eur J Clin Microbiol Infect Dis,2015,34(2):317-323.
[22]马明远,徐杰,于娜,等.头孢哌酮舒巴坦联合替加环素治疗肺部感染泛耐药鲍曼不动杆菌患者的疗效分析[J].中国中西医结合急救杂志,2013(6):349-352.
[23]Doi Y,Murray GL,Peleg AY.Acinetobacter baumannii: Evolution of Antimicrobial Resistance-Treatment Options[J].Seminars in Respiratory & Critical Care Medicine,2015,36(1):85-98.
[24]周华,周建英,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识解读[J].中国循证医学杂志,2016(1):26-29.
[25]柯倩,吕媛,王风娟.美罗培南联合舒巴坦或头孢哌酮-舒巴坦对多重耐药鲍曼不动杆菌的体外抗菌活性[J].中国感染与化疗杂志,2015,15(6):548-551.
[26]陆一丹,张亚莉,周浩.泛耐药鲍曼不动杆菌的体外联合药敏分析[J].南方医科大学学报,2014(11):1697-1701.
[27]Wisplinghoff H,Paulus T,Luqenheim M,et al.Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States[J].Journal of Infection,2012,64(3):282-290.
[28]Claeys KC,Fiorvento AD,Rybak MJ.A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii[J].Infect Dis Ther,2014,3(2):69-81.
[29]Batirel A,Balkan II, Karabay O,et al.Comparison of colistin-carbapenem,colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections[J].Eur J Clin Microbiol Infect Dis,2014,33(8):1311-1322.
[30]Shields RK,Kwak EJ,Potoski BA,et al.High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen[J].Diagnostic Microbiology & Infectious Disease,2011,70(2):246-252.
[31]Ni W,Shao X,Di X,et al.In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii:A systematic review and meta-analysis[J].International Journal of Antimicrobial Agents,2015,45(1):8-18.
[32]王健,沈继录.替加环素耐药机制的研究现状[J].中国感染与化疗杂志,2017,17(2):219-223.
[33]谭建龙,张卫东,柳威,等.替加环素治疗多或泛耐药鲍曼不动杆菌肺炎的疗效观察[J].中国呼吸与危重监护杂志,2013,12(6):581-585.
[34]Karageorgopoulos DE,Kelesidis T,Kelesidis I,et al.Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections:a review of the scientific evidence[J].J Antimicrob Chemother,2008,62(1):45-55.
[35]王风娟,吕媛,李耘.替加环素联合5种抗菌药物对多重耐药鲍曼不动杆菌的体外活性[J].中国临床药理学杂志,2013,29(5):345-349.
[36]庞晓军,周宏伟,韦华,等.时间差攻击疗法治疗多重耐药的鲍曼不动杆菌感染的探究[J].中国综合临床,2008,24(11):1138-1139.
[37]Montgomery AB,Rhomberg PR,Abuan T,et al.Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics[J].Antimicrob Agents Chemother,2014,58(7):3708-3713.
[38]晏奎,温汉春,陈一强,等.磷霉素联合左氧氟沙星对鲍曼不动杆菌生物膜的体外研究[J].中国临床药理学杂志,2015(4):276-278.
[39]Sirijatuphat R,Thamlikitkul V.Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections[J].Antimicrobial Agents & Chemotherapy,2014,58(9):5598-5601.
[40]Santimaleeworagun W,Wongpoowarak P,Chayakul P,et al.In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases[J].Southeast Asian J Trop Med Public Health,2011,42(4):890-900.

相似文献/References:

[1]张丽琴,刘 婷,刘 聪,等.赣南地区临床分离菌耐药性变迁及多重耐药菌的流行变化[J].医学信息,2018,31(05):123.[doi:10.3969/j.issn.1006-1959.2018.05.043]
 ZHANG Li-qin,LIU Ting,LIU Cong,et al.Changes of Drug Resistance of Clinical Isolates and Epidemic Changes of Multidrug-resistant Bacteria in Southern Guizhou[J].Medical Information,2018,31(05):123.[doi:10.3969/j.issn.1006-1959.2018.05.043]
[2]雷 敏.不孕不育患者解脲脲支原体培养及耐药性分析[J].医学信息,2018,31(06):156.[doi:10.3969/j.issn.1006-1959.2018.06.055]
 LEI Min.Analysis of Culture and Drug Resistance of Ureaplasma Urealyticum in Infertility Patients[J].Medical Information,2018,31(05):156.[doi:10.3969/j.issn.1006-1959.2018.06.055]
[3]高程凤,孙 蕊.新生儿败血症致病菌分布及耐药性分析[J].医学信息,2018,31(17):116.[doi:10.3969/j.issn.1006-1959.2018.17.035]
 GAO Cheng-feng,SUN Rui.Distribution and Drug Resistance of Pathogenic Bacteria in Neonatal Septicemia[J].Medical Information,2018,31(05):116.[doi:10.3969/j.issn.1006-1959.2018.17.035]
[4]张 美,王 欢,冯利芬.南京市江宁医院2015年~2017年血培养阳性病原菌分布及耐药性分析[J].医学信息,2018,31(20):108.[doi:10.3969/j.issn.1006-1959.2018.20.032]
 ZHANG Mei,WANG Huan,FENG Li-fen.Analysis of Distribution and Drug Resistance of Blood Culture Positive Pathogens in Jiangning Hospital of Nanjing from 2015 to 2017[J].Medical Information,2018,31(05):108.[doi:10.3969/j.issn.1006-1959.2018.20.032]
[5]于文清.下呼吸道感染病原菌分布及耐药性分析[J].医学信息,2018,31(24):74.[doi:10.3969/j.issn.1006-1959.2018.24.019]
 YU Wen-qing.Analysis of Distribution and Drug Resistance of Pathogenic Bacteria in Lower Respiratory Tract Infection[J].Medical Information,2018,31(05):74.[doi:10.3969/j.issn.1006-1959.2018.24.019]
[6]曾 江,邹 燕,刘 滨.耐甲氧西林金黄色葡萄球菌的临床分布及耐药性分析[J].医学信息,2019,32(02):148.[doi:10.3969/j.issn.1006-1959.2019.02.043]
 ZENG Jiang,ZOU Yan,LIU Bin.Clinical Distribution and Drug Resistance Analysis of Methicillin-resistant Staphylococcus Aureus[J].Medical Information,2019,32(05):148.[doi:10.3969/j.issn.1006-1959.2019.02.043]
[7]彭 杰,张 琴.儿童呼吸内科下呼吸道分离菌分布及药敏分析[J].医学信息,2019,32(03):134.[doi:10.3969/j.issn.1006-1959.2019.03.043]
 PENG Jie,ZHANG Qin.Distribution and Drug Sensitivity Analysis of Lower Respiratory Tract Isolates inChildren's Respiratory Medicine[J].Medical Information,2019,32(05):134.[doi:10.3969/j.issn.1006-1959.2019.03.043]
[8]何 静.上皮性卵巢癌化学治疗的研究[J].医学信息,2019,32(18):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
 HE Jing.Chemotherapy of Epithelial Ovarian Cancer[J].Medical Information,2019,32(05):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
[9]常 琪,魏韵佳,穆 琪,等.2016~2018年鲍曼不动杆菌临床分离株的 分布特征及耐药性变迁[J].医学信息,2019,32(16):119.[doi:10.3969/j.issn.1006-1959.2019.16.038]
 CHANG Qi,WEI Yun-jia,MU Qi,et al.Distribution Characteristics and Drug Resistance Changes of Clinical Isolates of Acinetobacter Baumannii from 2016 to 2018[J].Medical Information,2019,32(05):119.[doi:10.3969/j.issn.1006-1959.2019.16.038]
[10]吴方强,许夕海.2014~2018年我院耐碳青霉烯类肺炎克雷伯菌分布特点及感染患者的临床特点[J].医学信息,2019,32(24):28.[doi:10.3969/j.issn.1006-1959.2019.24.010]
 WU Fang-qiang,XU Xi-hai.Distribution Characteristics of Carbapenem-resistant Klebsiella Pneumoniae in our Hospital from 2014 to 2018 and Clinical Characteristics of Infected Patients[J].Medical Information,2019,32(05):28.[doi:10.3969/j.issn.1006-1959.2019.24.010]
[11]李淑惠.鲍曼不动杆菌临床分布及耐药性分析[J].医学信息,2018,31(03):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
 LI Shu-hui.Clinical Distribution and Drug Resistance of Acinetobacter Baumannii[J].Medical Information,2018,31(05):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]

更新日期/Last Update: 2019-03-01